Drug-induced acne with elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis

Brionna N. Hudson; Hollyann R. Jacobs; Alexander Philbrick; Xiaolong A. Zhou; Michelle M. Simonsen; Julie A. Safirstein; Shannon M. Rotolo

doi:10.1016/j.jcf.2022.09.002

Drug-induced acne with elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis

Brionna N. Hudson, Hollyann R. Jacobs, Alexander Philbrick, Xiaolong A. Zhou, Michelle M. Simonsen, Julie A. Safirstein, Shannon M. Rotolo^*

^*Corresponding author for this work

Dermatology

Research output: Contribution to journal › Article › peer-review

9 Scopus citations

Abstract

Elexacaftor/tezacaftor/ivacaftor (ELX-TEZ-IVA) is a Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) modulator shown to improve lung function and reduce sweat chloride in people with Cystic Fibrosis (CF). The only commonly reported dermatologic adverse effect with CFTR modulators including ELX-TEZ-IVA is rash. In this case series, we describe 19 patients who reported new onset or worsening of acne after initiation of this drug to their CF pharmacist or another member of their CF care team. The mechanism and frequency of this adverse effect is unknown.

Original language	English (US)
Pages (from-to)	1066-1069
Number of pages	4
Journal	Journal of Cystic Fibrosis
Volume	21
Issue number	6
DOIs	https://doi.org/10.1016/j.jcf.2022.09.002
State	Published - Nov 2022

Keywords

“Acne vulgaris”
“Cystic fibrosis”
“Drug-Related side effects and adverse reactions”
“Elexacaftor”

ASJC Scopus subject areas

Pediatrics, Perinatology, and Child Health
Pulmonary and Respiratory Medicine

Access to Document

10.1016/j.jcf.2022.09.002

Cite this

@article{8c1e3f6ff043469f85839b6902ed3a5f,

title = "Drug-induced acne with elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis",

abstract = "Elexacaftor/tezacaftor/ivacaftor (ELX-TEZ-IVA) is a Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) modulator shown to improve lung function and reduce sweat chloride in people with Cystic Fibrosis (CF). The only commonly reported dermatologic adverse effect with CFTR modulators including ELX-TEZ-IVA is rash. In this case series, we describe 19 patients who reported new onset or worsening of acne after initiation of this drug to their CF pharmacist or another member of their CF care team. The mechanism and frequency of this adverse effect is unknown.",

keywords = "“Acne vulgaris”, “Cystic fibrosis”, “Drug-Related side effects and adverse reactions”, “Elexacaftor”",

author = "Hudson, {Brionna N.} and Jacobs, {Hollyann R.} and Alexander Philbrick and Zhou, {Xiaolong A.} and Simonsen, {Michelle M.} and Safirstein, {Julie A.} and Rotolo, {Shannon M.}",

note = "Publisher Copyright: {\textcopyright} 2022 European Cystic Fibrosis Society",

year = "2022",

month = nov,

doi = "10.1016/j.jcf.2022.09.002",

language = "English (US)",

volume = "21",

pages = "1066--1069",

journal = "Journal of Cystic Fibrosis",

issn = "1569-1993",

publisher = "Elsevier",

number = "6",

}

TY - JOUR

T1 - Drug-induced acne with elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis

AU - Hudson, Brionna N.

AU - Jacobs, Hollyann R.

AU - Philbrick, Alexander

AU - Zhou, Xiaolong A.

AU - Simonsen, Michelle M.

AU - Safirstein, Julie A.

AU - Rotolo, Shannon M.

PY - 2022/11

Y1 - 2022/11

N2 - Elexacaftor/tezacaftor/ivacaftor (ELX-TEZ-IVA) is a Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) modulator shown to improve lung function and reduce sweat chloride in people with Cystic Fibrosis (CF). The only commonly reported dermatologic adverse effect with CFTR modulators including ELX-TEZ-IVA is rash. In this case series, we describe 19 patients who reported new onset or worsening of acne after initiation of this drug to their CF pharmacist or another member of their CF care team. The mechanism and frequency of this adverse effect is unknown.

AB - Elexacaftor/tezacaftor/ivacaftor (ELX-TEZ-IVA) is a Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) modulator shown to improve lung function and reduce sweat chloride in people with Cystic Fibrosis (CF). The only commonly reported dermatologic adverse effect with CFTR modulators including ELX-TEZ-IVA is rash. In this case series, we describe 19 patients who reported new onset or worsening of acne after initiation of this drug to their CF pharmacist or another member of their CF care team. The mechanism and frequency of this adverse effect is unknown.

KW - “Acne vulgaris”

KW - “Cystic fibrosis”

KW - “Drug-Related side effects and adverse reactions”

KW - “Elexacaftor”

UR - http://www.scopus.com/inward/record.url?scp=85137590179&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85137590179&partnerID=8YFLogxK

U2 - 10.1016/j.jcf.2022.09.002

DO - 10.1016/j.jcf.2022.09.002

M3 - Article

C2 - 36088208

AN - SCOPUS:85137590179

SN - 1569-1993

VL - 21

SP - 1066

EP - 1069

JO - Journal of Cystic Fibrosis

JF - Journal of Cystic Fibrosis

IS - 6

ER -

Drug-induced acne with elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this